Table 2. . Systemic therapy for metastatic melanoma.

Study (year)	Drug	Response rate (%)	Median survival (months)	Ref.
Michael et al. (1999)	IL-2	16	12	[14]
Hodi et al. (2010)	Ipilimumab (CTLA-4 inhibitor)	28.5	10	[18]
Omid et al. (2013)	Lambrolizumab (PD-1 Inhibitor)	62	Not reached	[19]
McArthur et al. (2014)	Vemurafenib (BRAF inhibitor)	57	13.6	[23]
Flaherty et al. (2012)	Trametinib (MEK inhibitor)	22	6 OS 81%	[24]

Disease control rate, complete partial and stable disease.

OS: Overall survival.